ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 419

Performance of Framingham Risk Factor Score in Predicting Cardiovascular Events in Patients with Polymyalgia Rheumatica

Florencia Beatriz Mollerach1, Sebastian Moyano1, Luciano Enrique Pompermayer1, Jose Maximiliano Martinez Perez2, Marina Scolnik3, Javier Rosa1, Luis J. Catoggio4 and Enrique R. Soriano1, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Rheumatology, Internal Medicine Service, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 3Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 4Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, polymyalgia rheumatica and risk assessment

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Quality Measures and Quality of Care - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  chronic inflammatory diseases are at a substantially increased risk of cardiovascular disease. Framingham risk score (FRS) underestimates cardiovascular risk in many inflammatory diseases. Our objective was to assess the predictive ability of Framingham score model for the 10-year risk of fatal and non-fatal CV diseases in patients with Polymyalgia Rheumatica (PMR).

Methods: we retrospectively reviewed electronic medical records of patients registered in our hospital after year 2000 with the diagnosis of PMR. Patients fulfilling ACR PMR 2012 criteria or with a clinical diagnose made by a rheumatologist were included. Patients with history of cardiovascular event before diagnosis, age greater of 80 years at diagnosis or with less than 10 years of follow up after diagnosis, were excluded. Framingham score was calculated at diagnosis, and based on the FRS, patients were classified into low, intermediate and high-risk categories. Cardiovascular (CV) events such as stroke, transient ischemic attack, coronary arterial disease and peripheral vasculopathy were identified during follow up. Discriminatory ability for CV risk prediction was estimated by the area under the receiver operating characteristic (ROC) curve. Global cardiovascular risk was calculated at 10 years after PMR diagnosis and compared with FRS estimated at diagnosis.

Results: A total of 97 patients were included. Patients characteristics are described in table. Among the 97 patients followed up for a total of 981.5 person-years, 18 CV events occurred with an incidence rate of 1.83 per 100 patient-years (95% CI: 1.1-2.9). There were no differences in clinical characteristics among patients with and without CV events (table). The area under the ROC curve for FRS was 0.61 (95% CI: 0.47- 0.74), indicating low discrimination between patients with and without a CV event. According to FRS 17 (17.5 %), 46 (47.4%) and 34 (35%) patients were classified into low, intermediate and high risk categories respectively. Across the three predicted CV risk groups the observed/predicted CV events (%) were:0.059/0.065; 0.2/0.13; and 0.24/0.26 for low, intermediate and high risk categories respectively. When observed vs predicted CV events in quintiles of CV risk were compared, the following values were obtained: 0.1 vs 0.072; 0.16 vs 0.12; 0.20 vs 0.16; 0.31 vs 0.34.

Conclusion: FRS showed low discrimination capacity between patients with and without a CV event. FRS primarily underestimated CV risk at low and intermediate risk levels, and mostly overestimated CV risk at higher risk levels. Table 1. Patients characteristics

Variables Patients with CV events (n=18) Patients without CV events (n= 79) p value
Females, n (%) 65 (82) 16 (89) 0.495
Mean age at diagnosis (SD) 73.5 (5.5) 71.9 (6.1) 0.3034
Mean erythrocyte sedimentation rate (SD) 60.2 (34.5) 59.9 (26.4) 0.9823
Mean Total cholesterol mg/L (SD) 208.3 (44) 213.7 (39.9) 0.6129
Diabetes at baseline, n (%) 3 (16.7) 5 (6.33) 0.150
Hypertension at baseline, n (%) 14 (77.8) 50 (63.3) 0.242
Obesity (BMI (weight(kg)/Height(m)2)>30, n (%) 5 (27.8) 17 (21.5) 0.567
Median FRS (IQR) 17.8 (12.4-26.6) 14.4 (10.8-21.9) 0.5404
Mean time follow up (years), (SD) 11.6 (1.6) 11.7 (1.7) 0.7761
Smoking, n (%)
Never 12 (67) 68 (86)
Former 3 (16.7) 6 (7.6) 0.177
Current 3 (16.7) 5 (6.3)

Disclosure: F. B. Mollerach, None; S. Moyano, None; L. E. Pompermayer, None; J. M. Martinez Perez, None; M. Scolnik, None; J. Rosa, None; L. J. Catoggio, None; E. R. Soriano, Abbvie, 2,Pfizer Inc, 3,UCB, 2,Janssen Pharmaceutica Product, L.P., 2,Roche Pharmaceuticals, 2,Bristol-Myers Squibb, 2,Abbvie, 5,Pfizer Inc, 5,UCB, 5,Janssen Pharmaceutica Product, L.P., 5,Roche Pharmaceuticals, 5,Novartis Pharmaceutical Corporation, 5,Bristol-Myers Squibb, 5.

To cite this abstract in AMA style:

Mollerach FB, Moyano S, Pompermayer LE, Martinez Perez JM, Scolnik M, Rosa J, Catoggio LJ, Soriano ER. Performance of Framingham Risk Factor Score in Predicting Cardiovascular Events in Patients with Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/performance-of-framingham-risk-factor-score-in-predicting-cardiovascular-events-in-patients-with-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2016

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-framingham-risk-factor-score-in-predicting-cardiovascular-events-in-patients-with-polymyalgia-rheumatica/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology